Search

Your search keyword '"Ray KK"' showing total 513 results

Search Constraints

Start Over You searched for: Author "Ray KK" Remove constraint Author: "Ray KK"
513 results on '"Ray KK"'

Search Results

1. Reduction in the risk of MACE with apabetalone in patients with recent acute coronary syndrome and diabetes according to NAFLD fibrosis score: exploratory analysis of the BETonMACE trial

2. Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes

3. P4608BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial

4. Evolocumab and clinical outcomes in patients with cardiovascular disease

6. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies.

7. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

8. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

9. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study

10. Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress

11. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study

12. The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration

13. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

14. BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial

17. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

18. The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study

19. Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study

22. Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1

23. LDL-cholesterol lowering strategies and population health - time to move to a cumulative exposure model

24. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action

25. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

26. Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies

27. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

29. Reducing the clinical and public health Burden of Familial hypercholesterolemia

30. Targeting PCSK9: Implications for basic science and upcoming challenges

31. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

32. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

33. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

34. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

35. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

36. Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes: The CARAT Trial

37. Major lipids, apolipoproteins, and risk of vascular disease

38. LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up

40. Inclisiran in patients with high CV risk and elevated LDL-cholesterol

42. Long-term mortality following acute myocardial infarction among those with and without diabetes: A systematic review and meta-analysis of studies in the post reperfusion era

43. Determining When to Add Nonstatin Therapy: A Quantitative Approach

44. Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI)

47. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

48. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials

50. Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK

Catalog

Books, media, physical & digital resources